Netherlands· NL-5fd8bfdacc9e
Descovy 200 mg/10 mg filmomhulde tabletten
A emtricitabine and tenofovir alafenamide product containing emtricitabine + tenofoviralafenamidefumaraat, registered in Netherlands by Gilead Sciences Ireland UC. The same ATC class is registered in 13 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Emtricitabine and tenofovir alafenamide is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AR17 (emtricitabine and tenofovir alafenamide), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Emtricitabine and tenofovir alafenamide · ATC J05AR17
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- EMTRICITABINE + TENOFOVIRALAFENAMIDEFUMARAAT
- Manufacturer
- Gilead Sciences Ireland UC
- Country
- Netherlands (NL)
- ATC code
- J05AR17
- ATC class
- Emtricitabine and tenofovir alafenamide
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/16/1099
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J05AR17
Emtricitabine and tenofovir alafenamide, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c5255c6c-40db-49cd-b062-8e7d582bf223 GET /v1/drugs/c5255c6c-40db-49cd-b062-8e7d582bf223?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/descovy-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Emtricitabine and tenofovir alafenamide",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp117532",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSCARMELLOSE NATRIUM (E 468)",
"IJZEROXIDE ZWART (E 172)",
"MACROGOL 3350",
"MAGNESIUMSTEARAAT (E 470b)",
"POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"EMTRICITABINE",
"TENOFOVIRALAFENAMIDEFUMARAAT"
],
"leaflet_url": null,
"authorised_at": "2016/04/21",
"procedure_number": "EMEA/H/C/004094",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/16/1099",
"additional_monitoring": "N"
}See everything about emtricitabine and tenofovir alafenamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.